TABLE 2.

Reduction of cefotaxime MIC in inhibiting bacterial growth^a

β-Lactamase	CTX MIC (μg/ml)	CTX + Cpd1 MIC (μg/ml)	Cpd1 MIC reduction (μg/ml)	CTX + Cla MIC (μg/ml)	Cla MIC reduction (μg/ml)
E. coli CTX-M-1	256–128	64–32	4	0.25	1,024–512
E. coli CTX-M-15	64	16	4	0.12	512
K. pneumoniae CTX-M-2	512–256	64–32	8	0.5	1,024–512
E. coli CTX-M-8	32–16	16–8	2	0.06	512–256
E. coli CTX-M-9	128	16	8	0.12	1,024
E. coli CTX-M-14	64	8	8	0.06	1,024
E. coli SHV-5	16	16		0.06	256
E. coli TEM-24	4	2	2	0.06	64
E. coli AmpC	8	4	2	8
E. coli OXA-48	0.5	0.25	2	0.5
E. coli NDM-1	32	32		32
K. pneumoniae KPC-2	16	16		0.5	32

^aCTX, cefotaxime; Cpd1, compound 1; Cla, clavulanate. Cefotaxime plus compound 1 and cefotaxime plus clavulanate were used at a 1:1 ratio.